+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sunitinib Malate Market by Indication (Gastrointestinal Stromal Tumor, Pancreatic Neuroendocrine Tumor, Renal Cell Carcinoma), Line Of Treatment (First Line, Second Line, Third Line), End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sunitinib Malate Market by Indication (Gastrointestinal Stromal Tumor, Pancreatic Neuroendocrine Tumor, Renal Cell Carcinoma), Line Of Treatment (First Line, Second Line, Third Line), End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Sunitinib Malate Market by Indication (Gastrointestinal Stromal Tumor, Pancreatic Neuroendocrine Tumor, Renal Cell Carcinoma), Line Of Treatment (First Line, Second Line, Third Line), End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 193 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6084048
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Sunitinib Malate Market continues to gain strategic importance in oncology, shaped by evolving treatment modalities, regional access dynamics, and complex supply-chain considerations. Senior decision-makers require a nuanced report tailored to current real-world pressures, regulatory flux, and the increasing role of precision medicine.

Market Snapshot: Sunitinib Malate Market Size and Growth

The Sunitinib Malate Market grew from USD 134.72 million in 2024 to USD 148.43 million in 2025. It is expected to continue growing at a CAGR of 9.90%, reaching USD 237.37 million by 2030. This trajectory demonstrates robust momentum driven by a combination of clinical innovation, favorable regulatory trends, and expanding adoption across a diverse set of oncology indications.

Scope & Segmentation

This report delivers actionable insights across a multi-faceted market landscape, equipping executives with clarity on adoption drivers, value-chain shifts, and essential operational metrics. It investigates:

  • Therapeutic Indications: Gastrointestinal stromal tumor (including Kit mutant, PDGFRA mutant, wild type); pancreatic neuroendocrine tumor (functional, non-functional); renal cell carcinoma (clear cell, non-clear cell).
  • Line of Treatment: First-line, second-line, and third-line therapy settings, mapping out shifts in practitioner prescribing and patient journey trajectories.
  • End User Segments: Hospital systems and specialty clinics, with a focus on inventory practices, service models, and patient support mechanisms.
  • Distribution Channel: Hospital pharmacies, online pharmacies, and retail pharmacies, detailing differences in fulfilment strategy and access models.
  • Regional Coverage: Americas (with U.S. state-level detail—California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio), Canada, Mexico, Brazil, Argentina; Europe, Middle East & Africa (including the U.K., Germany, France, Russia, Italy, Spain, UAE, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland); Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Industry Players: Pfizer Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Cadila Healthcare Ltd., Intas Pharmaceuticals Ltd.

Key Takeaways

  • Advancements in multi-receptor tyrosine kinase inhibition position sunitinib malate as a cornerstone in modern oncology, supporting therapeutic strategies across previously difficult-to-treat malignancies.
  • There is a growing emphasis on personalized medicine, enabled by biomarker-driven stratification and precision diagnostics that drive better patient matching and improved clinical outcomes.
  • Combination regimens involving sunitinib malate with immunotherapy or other targeted agents demonstrate increasing clinical relevance, influencing guideline updates and therapy sequencing.
  • Collaboration trends include strategic partnerships for lifecycle management, co-development of new formulations, and shared-risk approaches to accelerate approval of combination therapies.
  • Differentiated segmentation by indication, end user, and channel is critical for manufacturers and distributors seeking to optimize geographic reach and service quality.
  • Regulatory shifts towards adaptive approval and use of real-world evidence are facilitating faster access and broader label extensions, while highlighting the need for ongoing surveillance and safety management.

Tariff Impact on Sunitinib Malate Supply Chains

New United States tariffs enacted in 2025 have altered the cost structure along the sunitinib malate value chain. These measures increase procurement complexity and manufacturing expenses, compelling manufacturers to reconsider sourcing strategies and enhance supply-chain resilience. Clinical trial sponsors and contract development organizations also face additional compliance and logistics hurdles, affecting site selection and study execution timelines. Mitigation approaches include near-shoring, expanded inventory buffers, and decentralized distribution models, which help sustain patient access in the face of tariff-related disruptions.

Methodology & Data Sources

Findings are drawn from a combination of primary interviews with key opinion leaders, payers, and supply experts, as well as secondary sources such as regulatory filings, clinical literature, and proprietary market databases. Quantitative insights are validated by advanced statistical analysis and triangulation, ensuring transparent, unbiased perspectives for decision-makers.

Why This Report Matters

  • Gain 360-degree visibility into the sunitinib malate market supported by deep segmentation and competitive landscape profiling.
  • Leverage strategic recommendations to address region-specific regulatory and commercial challenges, supporting both portfolio planning and tactical execution.
  • Inform product development, pricing, and partnership decisions with up-to-date, expert-vetted intelligence tailored to senior stakeholders.

Conclusion

Sunitinib malate’s evolving clinical profile and competitive landscape demand adaptive strategy and operational agility. This report offers the evidence base and actionable guidance senior leaders require to navigate future market and policy developments with confidence.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of sunitinib malate combinations in refractory renal cell carcinoma treatment lines
5.2. Impact of emerging biosimilars on pricing dynamics and patient access to sunitinib malate
5.3. Integration of real-world evidence in evaluating sunitinib malate long-term safety profiles
5.4. Expansion of personalized dosing regimens based on pharmacogenomic markers in sunitinib therapy
5.5. Influence of health policy reforms on reimbursement rates for sunitinib malate across major markets
5.6. Development of novel delivery systems to improve sunitinib malate bioavailability and patient adherence
5.7. Strategic biopharma collaborations accelerating next-generation VEGFR inhibitor research for sunitinib successors
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Sunitinib Malate Market, by Indication
8.1. Introduction
8.2. Gastrointestinal Stromal Tumor
8.2.1. Kit Mutant
8.2.2. Pdgra Mutant
8.2.3. Wild Type
8.3. Pancreatic Neuroendocrine Tumor
8.3.1. Functional
8.3.2. Non Functional
8.4. Renal Cell Carcinoma
8.4.1. Clear Cell Carcinoma
8.4.2. Non-Clear Cell Carcinoma
9. Sunitinib Malate Market, by Line Of Treatment
9.1. Introduction
9.2. First Line
9.3. Second Line
9.4. Third Line
10. Sunitinib Malate Market, by End User
10.1. Introduction
10.2. Hospital
10.3. Specialty Clinic
11. Sunitinib Malate Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Americas Sunitinib Malate Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Sunitinib Malate Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Sunitinib Malate Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Pfizer Inc.
15.3.2. Viatris Inc.
15.3.3. Teva Pharmaceutical Industries Ltd.
15.3.4. Sandoz International GmbH
15.3.5. Dr. Reddy's Laboratories Ltd.
15.3.6. Sun Pharmaceutical Industries Ltd.
15.3.7. Cipla Ltd.
15.3.8. Aurobindo Pharma Ltd.
15.3.9. Cadila Healthcare Ltd.
15.3.10. Intas Pharmaceuticals Ltd.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. SUNITINIB MALATE MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL SUNITINIB MALATE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL SUNITINIB MALATE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SUNITINIB MALATE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SUNITINIB MALATE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. SUNITINIB MALATE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. SUNITINIB MALATE MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. SUNITINIB MALATE MARKET: RESEARCHAI
FIGURE 24. SUNITINIB MALATE MARKET: RESEARCHSTATISTICS
FIGURE 25. SUNITINIB MALATE MARKET: RESEARCHCONTACTS
FIGURE 26. SUNITINIB MALATE MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. SUNITINIB MALATE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SUNITINIB MALATE MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL SUNITINIB MALATE MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL SUNITINIB MALATE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL SUNITINIB MALATE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL SUNITINIB MALATE MARKET SIZE, BY KIT MUTANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL SUNITINIB MALATE MARKET SIZE, BY KIT MUTANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PDGRA MUTANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PDGRA MUTANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL SUNITINIB MALATE MARKET SIZE, BY WILD TYPE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL SUNITINIB MALATE MARKET SIZE, BY WILD TYPE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL SUNITINIB MALATE MARKET SIZE, BY FUNCTIONAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL SUNITINIB MALATE MARKET SIZE, BY FUNCTIONAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL SUNITINIB MALATE MARKET SIZE, BY NON FUNCTIONAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL SUNITINIB MALATE MARKET SIZE, BY NON FUNCTIONAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL SUNITINIB MALATE MARKET SIZE, BY CLEAR CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL SUNITINIB MALATE MARKET SIZE, BY CLEAR CELL CARCINOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL SUNITINIB MALATE MARKET SIZE, BY NON-CLEAR CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL SUNITINIB MALATE MARKET SIZE, BY NON-CLEAR CELL CARCINOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL SUNITINIB MALATE MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL SUNITINIB MALATE MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL SUNITINIB MALATE MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL SUNITINIB MALATE MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL SUNITINIB MALATE MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL SUNITINIB MALATE MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL SUNITINIB MALATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL SUNITINIB MALATE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL SUNITINIB MALATE MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL SUNITINIB MALATE MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL SUNITINIB MALATE MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL SUNITINIB MALATE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL SUNITINIB MALATE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL SUNITINIB MALATE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL SUNITINIB MALATE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL SUNITINIB MALATE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS SUNITINIB MALATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES SUNITINIB MALATE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 91. CANADA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 92. CANADA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 93. CANADA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2024 (USD MILLION)
TABLE 94. CANADA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2025-2030 (USD MILLION)
TABLE 95. CANADA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2024 (USD MILLION)
TABLE 96. CANADA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2025-2030 (USD MILLION)
TABLE 97. CANADA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 98. CANADA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 99. CANADA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2024 (USD MILLION)
TABLE 100. CANADA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2025-2030 (USD MILLION)
TABLE 101. CANADA SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 102. CANADA SUNITINIB MALATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 103. CANADA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 104. CANADA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 105. MEXICO SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 106. MEXICO SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 107. MEXICO SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2024 (USD MILLION)
TABLE 108. MEXICO SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2025-2030 (USD MILLION)
TABLE 109. MEXICO SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2024 (USD MILLION)
TABLE 110. MEXICO SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2025-2030 (USD MILLION)
TABLE 111. MEXICO SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 112. MEXICO SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 113. MEXICO SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2024 (USD MILLION)
TABLE 114. MEXICO SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2025-2030 (USD MILLION)
TABLE 115. MEXICO SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 116. MEXICO SUNITINIB MALATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 117. MEXICO SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 118. MEXICO SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2025-2030 (USD MILLION)
TABLE 123. BRAZIL SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2024 (USD MILLION)
TABLE 124. BRAZIL SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2025-2030 (USD MILLION)
TABLE 125. BRAZIL SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 126. BRAZIL SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL SUNITINIB MALATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 135. ARGENTINA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2024 (USD MILLION)
TABLE 136. ARGENTINA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2025-2030 (USD MILLION)
TABLE 137. ARGENTINA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2024 (USD MILLION)
TABLE 138. ARGENTINA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2025-2030 (USD MILLION)
TABLE 139. ARGENTINA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 140. ARGENTINA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 141. ARGENTINA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2024 (USD MILLION)
TABLE 142. ARGENTINA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA SUNITINIB MALATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2024 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2025-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2024 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2025-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA SUNITINIB MALATE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 164. UNITED KINGDOM SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2024 (USD MILLION)
TABLE 166. UNITED KINGDOM SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2025-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2024 (USD MILLION)
TABLE 168. UNITED KINGDOM SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2025-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 170. UNITED KINGDOM SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2024 (USD MILLION)
TABLE 172. UNITED KINGDOM SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2025-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. UNITED KINGDOM SUNITINIB MALATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. UNITED KINGDOM SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. GERMANY SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 178. GERMANY SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 179. GERMANY SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2024 (USD MILLION)
TABLE 180. GERMANY SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2025-2030 (USD MILLION)
TABLE 181. GERMANY SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2024 (USD MILLION)
TABLE 182. GERMANY SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2025-2030 (USD MILLION)
TABLE 183. GERMANY SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 184. GERMANY SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 185. GERMANY SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2024 (USD MILLION)
TABLE 186. GERMANY SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2025-2030 (USD MILLION)
TABLE 187. GERMANY SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 188. GERMANY SUNITINIB MALATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 189. GERMANY SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 190. GERMANY SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 191. FRANCE SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 192. FRANCE SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 193. FRANCE SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2024 (USD MILLION)
TABLE 194. FRANCE SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2025-2030 (USD MILLION)
TABLE 195. FRANCE SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2024 (USD MILLION)
TABLE 196. FRANCE SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2025-2030 (USD MILLION)
TABLE 197. FRANCE SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 198. FRANCE SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 199. FRANCE SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2024 (USD MILLION)
TABLE 200. FRANCE SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2025-2030 (USD MILLION)
TABLE 201. FRANCE SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 202. FRANCE SUNITINIB MALATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 203. FRANCE SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. FRANCE SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. RUSSIA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 206. RUSSIA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 207. RUSSIA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2024 (USD MILLION)
TABLE 208. RUSSIA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2025-2030 (USD MILLION)
TABLE 209. RUSSIA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2024 (USD MILLION)
TABLE 210. RUSSIA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2025-2030 (USD MILLION)
TABLE 211. RUSSIA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 212. RUSSIA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 213. RUSSIA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2024 (USD MILLION)
TABLE 214. RUSSIA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2025-2030 (USD MILLION)
TABLE 215. RUSSIA SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. RUSSIA SUNITINIB MALATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. RUSSIA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. RUSSIA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. ITALY SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 220. ITALY SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 221. ITALY SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2024 (USD MILLION)
TABLE 222. ITALY SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2025-2030 (USD MILLION)
TABLE 223. ITALY SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2024 (USD MILLION)
TABLE 224. ITALY SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2025-2030 (USD MILLION)
TABLE 225. ITALY SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 226. ITALY SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 227. ITALY SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2024 (USD MILLION)
TABLE 228. ITALY SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2025-2030 (USD MILLION)
TABLE 229. ITALY SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. ITALY SUNITINIB MALATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. ITALY SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. ITALY SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. SPAIN SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 234. SPAIN SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 235. SPAIN SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2024 (USD MILLION)
TABLE 236. SPAIN SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2025-2030 (USD MILLION)
TABLE 237. SPAIN SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2024 (USD MILLION)
TABLE 238. SPAIN SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2025-2030 (USD MILLION)
TABLE 239. SPAIN SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 240. SPAIN SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 241. SPAIN SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2024 (USD MILLION)
TABLE 242. SPAIN SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2025-2030 (USD MILLION)
TABLE 243. SPAIN SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 244. SPAIN SUNITINIB MALATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 245. SPAIN SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. SPAIN SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2024 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2025-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2024 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2025-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2024 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2025-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES SUNITINIB MALATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 262. SAUDI ARABIA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2024 (USD MILLION)
TABLE 264. SAUDI ARABIA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2025-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2024 (USD MILLION)
TABLE 266. SAUDI ARABIA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2025-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 268. SAUDI ARABIA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2024 (USD MILLION)
TABLE 270. SAUDI ARABIA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2025-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 272. SAUDI ARABIA SUNITINIB MALATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 274. SAUDI ARABIA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 276. SOUTH AFRICA SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2024 (USD MILLION)
TABLE 278. SOUTH AFRICA SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2025-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2024 (USD MILLION)
TABLE 280. SOUTH AFRICA SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2025-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 282. SOUTH AFRICA SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2024 (USD MILLION)
TABLE 284. SOUTH AFRICA SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2025-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. SOUTH AFRICA SUNITINIB MALATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 288. SOUTH AFRICA SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 289. DENMARK SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 290. DENMARK SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 291. DENMARK SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2024 (USD MILLION)
TABLE 292. DENMARK SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2025-2030 (USD MILLION)
TABLE 293. DENMARK SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2024 (USD MILLION)
TABLE 294. DENMARK SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2025-2030 (USD MILLION)
TABLE 295. DENMARK SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 296. DENMARK SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 297. DENMARK SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2024 (USD MILLION)
TABLE 298. DENMARK SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2025-2030 (USD MILLION)
TABLE 299. DENMARK SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 300. DENMARK SUNITINIB MALATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 301. DENMARK SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 302. DENMARK SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 303. NETHERLANDS SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 304. NETHERLANDS SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 305. NETHERLANDS SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2024 (USD MILLION)
TABLE 306. NETHERLANDS SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2025-2030 (USD MILLION)
TABLE 307. NETHERLANDS SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2024 (USD MILLION)
TABLE 308. NETHERLANDS SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2025-2030 (USD MILLION)
TABLE 309. NETHERLANDS SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 310. NETHERLANDS SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 311. NETHERLANDS SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2024 (USD MILLION)
TABLE 312. NETHERLANDS SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2025-2030 (USD MILLION)
TABLE 313. NETHERLANDS SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 314. NETHERLANDS SUNITINIB MALATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 315. NETHERLANDS SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 316. NETHERLANDS SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 317. QATAR SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 318. QATAR SUNITINIB MALATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 319. QATAR SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2018-2024 (USD MILLION)
TABLE 320. QATAR SUNITINIB MALATE MARKET SIZE, BY GASTROINTESTINAL STROMAL TUMOR, 2025-2030 (USD MILLION)
TABLE 321. QATAR SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2018-2024 (USD MILLION)
TABLE 322. QATAR SUNITINIB MALATE MARKET SIZE, BY PANCREATIC NEUROENDOCRINE TUMOR, 2025-2030 (USD MILLION)
TABLE 323. QATAR SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2018-2024 (USD MILLION)
TABLE 324. QATAR SUNITINIB MALATE MARKET SIZE, BY RENAL CELL CARCINOMA, 2025-2030 (USD MILLION)
TABLE 325. QATAR SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2018-2024 (USD MILLION)
TABLE 326. QATAR SUNITINIB MALATE MARKET SIZE, BY LINE OF TREATMENT, 2025-2030 (USD MILLION)
TABLE 327. QATAR SUNITINIB MALATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 328. QATAR SUNITINIB MALATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 329. QATAR SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 330. QATAR SUNITINIB MALATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Sunitinib Malate market report include:
  • Pfizer Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Cipla Ltd.
  • Aurobindo Pharma Ltd.
  • Cadila Healthcare Ltd.
  • Intas Pharmaceuticals Ltd.

Table Information

Report AttributeDetails
No. of Pages193
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 148.43 Million
Forecasted Market Value ( USD ) by 2030 $ 237.37 Million
Compound Annual Growth Rate9.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Sunitinib Malate - Global Strategic Business Report - Product Image

Sunitinib Malate - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Sunitinib Malate (CAS 341031-54-7) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Sunitinib Malate (CAS 341031-54-7) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Sunitinib (CAS 557795-19-4) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Sunitinib (CAS 557795-19-4) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Pancreatic Cancer Drug Pipeline Analysis Report 2025 - Product Image

Pancreatic Cancer Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From

About the Sunitinib Malate Market

Sunitinib malate, marketed under the brand name Sutent among others, falls within the category of targeted oncology drugs, specifically acting as a multi-targeted receptor tyrosine kinase (RTK) inhibitor. Its market presence is dictated by its efficacy in treating various types of cancer, including renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors (PNETs). Sunitinib malate operates by blocking multiple molecular targets implicated in the growth, proliferation, and spread of cancer cells. Due to its targeted approach, it represents an alternative to conventional chemotherapy, offering a different side effect profile and method of action. Its utility in the field of oncology continues to be explored with ongoing research assessing its potential application in other malignancies. Several pharmaceutical and biotechnology companies have a stake in the market for sunitinib malate. Pfizer Inc. is the most prominent as the originator and manufacturer of Sutent, the landmark brand of sunitinib. Other companies may be involved in the distribution or production of generic forms of the drug. These include but are not limited to Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Mylan N.V. This market is subject to the stringent regulations and patent laws related to novel oncology therapies, which influence the competitive landscape as well as the availability of generic versions. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.